

**Fiscal Year 2026 Congressionally Directed Medical Research Programs  
Duchenne Muscular Dystrophy Research Program (DMDRP)  
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942526DMDRPIDA</p>	<p><b>Established Investigators:</b> Independent investigators at all academic levels, or equivalent.</p> <p><b>New Investigators – Early Stage:</b> Independent investigators that, by the application submission deadline date:</p> <ul style="list-style-type: none"> <li>• Are <b>within 10 years</b> of first faculty appointment, or equivalent.</li> <li>• Have not previously received a DMDRP Idea Development Award.</li> </ul> <p><b>New Investigators – Transitioning:</b> Established independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy seeking to transition to a career in DMD, thereby bringing their expertise to the field.</p> <p>Investigators must pursue an active line of research in DMD and commit at least 10% of their efforts during each budget year toward the proposed DMD research project.</p>	<ul style="list-style-type: none"> <li>• Supports the development of impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD in the near term.</li> <li>• Research <b>must</b> address opportunities and challenges in the development of safe and effective therapies that focus on primary pathology of DMD.</li> <li>• The DMDRP <b>strongly</b> encourages research projects investigating therapies that are efficacious across the lifespan.</li> <li>• <b>Preliminary data relevant to DMD is required.</b></li> <li>• <b>Clinical trials are not allowed.</b></li> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$500,000</b> for total costs.*</li> </ul> <p>The maximum period of performance is <b>2</b> years.</p>	<p><b>Pre-Application (Letter of Intent):</b> September 4, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 18, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical/Translational Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942526DMDRPECTRA</p>	<p><b>Established Investigators:</b> Independent investigators at all academic levels, or equivalent.</p> <p><b>Partnering PI Option:</b> The partnering PI must be:</p> <ul style="list-style-type: none"> <li>An independent, early-career investigator within 10 years of their first faculty appointment by the time of application submission. Applications should explain lapses in research time or appointments in the biographical sketch.</li> <li><i>or</i></li> <li>An established interdisciplinary PI from an area other than muscular dystrophy seeking to develop research in DMD, thereby bringing their expertise to the field.</li> </ul>	<ul style="list-style-type: none"> <li>Supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications.</li> <li>Research must address the FY26 CTRA- Focus Areas.</li> <li>The DMDRP <b>strongly</b> encourages research projects investigating therapies that will be efficacious across the lifespan.</li> <li><b>Preliminary data is required.</b></li> <li>Clinical trials and clinical research are allowed.</li> <li><b>Partnering Principal Investigator Option:</b> Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.</li> <li>Different Funding Levels, based on the scope of research, are available. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research. The Funding Level should be selected based on the research scope and not on the amount of the budget. <ul style="list-style-type: none"> <li><b>Funding Level 1:</b> Supports smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed.</li> <li><b>Funding Level 2:</b> Supports larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed.</li> </ul> </li> <li><b>Submission of a Letter of Intent is required prior to full application submission.</b></li> </ul>	<p><b>Funding Level 1:</b></p> <p><b>Single PI</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$910,000</b> for total costs.*</li> <li>The maximum period of performance is <b>3</b> years.</li> </ul> <p><b>Partnering PI Option</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$1.0 million (M)</b> for total costs.*</li> <li>The maximum period of performance is <b>3</b> years.</li> </ul> <p><b>Funding Level 2:</b></p> <p><b>Single PI</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$1.75M</b> for total costs.*</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul> <p><b>Partnering PI Option</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$1.9M</b> for total costs.*</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 4, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 18, 2026 11:59 p.m. Eastern time</p>

\*Total costs include direct and indirect costs.